Martin Mackay - 16 Apr 2026 Form 4 Insider Report for Kailera Therapeutics, Inc. (KLRA)

Reporting relationship: Director
Issuer ticker: KLRA
Reported as of: 16 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Apr 2026, 17:10:09 UTC
Prior SEC filing: 20 Feb 2026
Next SEC filing: 11 May 2026
Source filing: View source filing
Reporting owner signature: /s/ John Mei, Attorney-in-fact

Key filing fact

Martin Mackay filed Form 4 for Kailera Therapeutics, Inc. (KLRA) on 20 Apr 2026.

Key facts

This page summarizes Martin Mackay's Form 4 filing for Kailera Therapeutics, Inc. (KLRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Apr 2026, 17:10.

Change

Previous filing in this sequence was filed on 20 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001414815 Primary reporting owner

MACKAY MARTIN

Relationship: Director
Address: C/O KAILERA THERAPEUTICS, INC., 180 THIRD AVENUE, 4TH FLOOR, WALTHAM
Signature: /s/ John Mei, Attorney-in-fact
Signature date: 20 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KLRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +38,300
Change %
Price: $0.000000^*
Shares after: 38,300
Date: 16 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,300
Exercise price: $16.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.